Restricted Win Probability with Bayesian Estimation for Implementing the Estimand Framework in Clinical Trials With a Time-to-Event Outcome
Michelle Leeberg, Xianghua Luo, Thomas A. Murray

TL;DR
This paper introduces a Bayesian method for estimating a restricted win probability in clinical trials with time-to-event data, improving power and interpretability within the estimand framework.
Contribution
It proposes a novel Bayesian estimand and estimator for restricted win probability, enhancing handling of censoring and aligning with the estimand framework in survival analysis.
Findings
More power than log-rank test in early difference scenarios
Comparable power to win ratio across scenarios
High concordance with log-rank test in oncology datasets
Abstract
We propose a restricted win probability estimand for comparing treatments in a randomized trial with a time-to-event outcome. We also propose Bayesian estimators for this summary measure as well as the unrestricted win probability. Bayesian estimation is scalable and facilitates seamless handling of censoring mechanisms as compared to related non-parametric pairwise approaches like win ratios. Unlike the log-rank test, these measures effectuate the estimand framework as they reflect a clearly defined population quantity related to the probability of a later event time with the potential restriction that event times exceeding a pre-specified time are deemed equivalent. We compare efficacy with established methods using computer simulation and apply the proposed approach to 304 reconstructed datasets from oncology trials. We show that the proposed approach has more power than the log-rank…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsStatistical Methods in Clinical Trials · Health Systems, Economic Evaluations, Quality of Life · Pharmaceutical Economics and Policy
